LPCN - Lipocine Inc
IEX Last Trade
3.56
-0.030 -0.843%
Share volume: 4,864
Last Updated: Fri 30 Aug 2024 08:45:31 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$3.59
-0.03
-0.84%
Fundamental analysis
24%
Profitability
25%
Dept financing
15%
Liquidity
50%
Performance
19%
Performance
5 Days
0 0%
1 Month
-26.75%
3 Months
-47.04%
6 Months
-5.41%
1 Year
-8.25%
2 Year
-62.83%
Key data
Stock price
$3.56
DAY RANGE
N/A - N/A
52 WEEK RANGE
$2.31 - $11.79
52 WEEK CHANGE
-$0.02
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Mahesh Patel
Region: US
Website: https://www.lipocine.com/
Employees: 19
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.lipocine.com/
Employees: 19
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah.
Recent news